-

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.

Panel Discussion Details:

Speaker: Robin Taylor, Ph.D., Chief Commercial Officer

Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’

Date: 02/28/2025

Time: 1:00-2:00 p.m. ET

Location: New York City, NY

This event is for in-person participants only. Contact B. Riley for information on attending the conference.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Investors
917-362-1370
investor@agenusbio.com

Media
510-323-5188
communications@agenusbio.com

Industry:

Agenus Inc.

NASDAQ:AGEN
Release Versions
English

Contacts

Investors
917-362-1370
investor@agenusbio.com

Media
510-323-5188
communications@agenusbio.com

More News From Agenus Inc.

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poste...

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care. Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system...

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipat...
Back to Newsroom